Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LENSAR, a medical technology company, reported its financial results for Q4 and full year 2022. Total revenue for Q4 decreased by 9% to $10.2 million, primarily due to lower procedure revenue in South Korea. Despite this, the year-end revenue of $35.4 million represented a 3% increase from 2021. The company installed ten ALLY Adaptive Cataract Treatment Systems by year-end and signed contracts for six more. Selling, general and administrative expenses rose by 24%, reflecting increased marketing efforts. LENSAR aims for over 20% revenue growth in 2023 as it fully launches the ALLY System.
LENSAR, Inc. (NASDAQ: LNSR), a leader in medical technology focused on femtosecond laser surgical solutions for cataracts, will release its fourth quarter and full year 2022 financial results on March 16, 2023, before the market opens. A conference call will follow at 8:30 am ET the same day to discuss the results and corporate updates. Interested parties can join the call by dialing (888) 886 7786 for domestic or (416) 764 8658 for international access, using conference ID 94867603. The company’s innovative ALLY® Adaptive Cataract Treatment System aims to enhance surgical efficiency and outcomes.